KRM22 Achieves Maiden Adjusted EBITDA Profit Amid 22% ARR Growth in 2024
KRM22 swings to £1m EBITDA profit with 22% ARR growth. Why this regulatory tech milestone matters for investors.
This article covers information on KRM22 PLC.
LON:KRMKRM22 Hits Profitability Milestone: Why This Matters for Investors
Let’s raise a cuppa to milestones, shall we? KRM22 just delivered its first-ever adjusted EBITDA profit – a £1m swing from last year’s £1.4m loss. For a company that’s been playing the long game in capital markets risk tech, this isn’t just progress – it’s proof the strategy’s gaining serious traction.
The Numbers That Made 2024 Sparkle
- ARR rocket fuel: 22% annual growth to £6.6m (already £7.4m post-year-end)
- Revenue surge: 28% increase to £6.8m, with 92% from recurring contracts
- Cost discipline: £1.2m annual savings from restructuring – leaner but not meaner
Behind the Scenes: How They Pulled It Off
New CEO Dan Carter didn’t just rearrange the deckchairs. The 2024 playbook had three winning moves:
1. Product Innovation That Sticks
Their new Risk Manager application contributed 48% of new ARR – like launching a hit single that immediately tops the charts. Meanwhile, Limits Manager and Market Surveillance kept existing clients spending more (31% and 19% of new ARR respectively).
2. Strategic Partnerships With Teeth
The Trading Technologies (TT) relationship isn’t just a press release fling – it’s delivering £0.9m ARR and crucial deferred loan terms. This isn’t dating; it’s a full-blown financial marriage with shared tech integration.
3. Surgical Cost Management
That £1.2m savings didn’t come from skipping biscuits in the breakroom. Streamlined ops and focused R&D (still £1.1m capitalised) show maturity – spending smart, not just spending less.
The Elephant in the Boardroom: That TT Convertible Loan
Let’s not gloss over the £5.3m debt overhang. The recent amendments (deferring interest until 2026) buy breathing room, but covenant risks remain. My take? This looks manageable if ARR growth stays above 20%. The key dates to watch:
- December 2025 cash covenant test
- June 2026 loan maturity
Why Capital Markets Are Biting
As Garry Jones notes, volatility is the new normal. With regulators dishing out fines like parking tickets, KRM22’s sweet spot – real-time risk analytics – couldn’t be timelier. Their push into equities/FX/crypto (beyond core derivatives) could triple their £6bn SaaS market slice.
2025 Outlook: Runway Lights Are Green
With £7.4m ARR already banked and:
- TT partnership scaling up surveillance sales
- AI enhancements rolling out in Market Surveillance
- Multi-asset expansion underway
This could be the inflection point growth investors crave. But keep your eyes on two metrics: gross retention (currently 92%) and TT-related ARR concentration (currently 14%).
Final Thought: More Than Just a Profit
KRM22’s not just selling software – they’re selling financial stability in unstable times. That first EBITDA profit isn’t a finish line; it’s proof their product-market fit works. As risk management shifts from compliance checkbox to competitive advantage, this AIM player might just become a mainstage act.
Related
Keep reading
Investing
Ten Technologies Preliminary Results 2026: Record EBITDA and Member Growth
Ten Technologies delivered record 2026 results as active members rose 23% and adjusted EBITDA increased 10% to £16.1 million.
JoshuaNovember 11, 2026
Investing
Winvia Entertainment completes The Online Giveaway Guys acquisition
Winvia Entertainment has completed its purchase of The Online Giveaway Guys' business and key assets, excluding liabilities, cash and receivables.
JoshuaNovember 10, 2026
Investing
RUA Life Sciences reaches positive adjusted EBITDA as Structural Heart spin-out reshapes the group
RUA Life Sciences expects £5.5 million revenue and £0.3 million adjusted EBITDA, but ABISS weakness and lower cash warrant attention.
JoshuaNovember 9, 2026
Tagged
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.